Baylor Medicine’s Interstitial Lung Disease (ILD) program offers specialized and multidisciplinary care. We bring together a unique team of physicians of multiple sub-specialties for patients with a ...

At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...

Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma (DHG), new research has found. Diffuse hemispheric glioma is a rare, high-grade ...

The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only ...

Ribociclib in combination with an aromatose inhibitor for previously untreated advanced or metastatic hormone receptor-positive, her2-negative breast cancer. The NICE appraisal committee wanted to ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Diffuse (interstitial) lung disease includes a wide variety of relatively uncommon conditions presenting with characteristic clusters of clinical features and marked by an immune response. There ...

Interstitial lung disease (ILD) is a broad term for a group of conditions that cause lung inflammation and/or fibrosis ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...